A5026759066- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Liver Diseases and Immunity
- Pancreatic and Hepatic Oncology Research
- Vaccine Coverage and Hesitancy
- Diet, Metabolism, and Disease
- Alcohol Consumption and Health Effects
- Acute Lymphoblastic Leukemia research
- Gout, Hyperuricemia, Uric Acid
- Listeria monocytogenes in Food Safety
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Immunotherapy and Immune Responses
- Healthcare Systems and Reforms
- Salmonella and Campylobacter epidemiology
- Childhood Cancer Survivors' Quality of Life
- Poxvirus research and outbreaks
- Cassava research and cyanide
- SARS-CoV-2 detection and testing
Ministry of Health and Welfare
2019-2025
Kaohsiung Medical University
2016-2025
Kaohsiung Medical University Chung-Ho Memorial Hospital
2016-2025
National Health Research Institutes
2023-2025
Pingtung Hospital
2019-2025
Weatherford College
2022
INTRODUCTION: It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differ in their effectiveness for preventing hepatocellular carcinoma (HCC) patients with chronic hepatitis B (CHB). METHODS: This retrospective cohort study analyzed an international consortium that encompassed 19 centers from 6 countries or regions composed of previously untreated CHB then treated either ETV TDF monotherapy. Those who developed HCC before antiviral treatment within 1 year therapy...
Abstract Background/Aims Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the best policies to control COVID-19 pandemic. The serological response vaccination in Taiwanese patients with different comorbidities elusive. Methods Uninfected subjects who received 3 doses mRNA vaccines (BNT162b2 [Pfizer-BioNTech, BNT] and mRNA-1273 [Moderna]), viral vector-based (ChAdOx1-S (AZD1222, AZ) or protein subunit (Medigen vaccine) were prospectively enrolled....
Air pollution is a risk factor for hepatocellular carcinoma (HCC). However, the effect of air on HCC in patients with hepatitis remains unclear.
Background: To investigate the association between air pollution and abnormal alanine aminotransferase levels in patients with chronic hepatitis B treated nucleotide/nucleoside analogs. Methods: This cross-sectional study enrolled 1,275 analogs from 2019 to 2022 Kaohsiung analyzed incidence risk factors for levels. Daily pollutant concentrations were estimated year prior enrolment. Results: Abnormal observed 1,127 (88.4%) before treatment (NAs). Logistic regression analysis revealed that...
ABSTRACT Background and Aims Air pollution is associated with advanced liver fibrosis in patients chronic diseases, including hepatitis B (CHB). This study aimed to investigate the association between air mortality CHB treated nucleotide/nucleoside analogues. Methods We enrolled 697 analogues analysed incidence risk factors for mortality. Daily pollutant concentrations were estimated from year before enrolment. Results All‐cause showed an annual of 1.1/100 person‐years after a follow‐up...
BACKGROUND Insulin resistance, lipotoxicity, and mitochondrial dysfunction contribute to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). Mitochondrial impairs oxidative phosphorylation increases reactive oxygen species production, leading steatohepatitis hepatic fibrosis. Artificial intelligence (AI) is a potent tool for diagnosis risk stratification. AIM To investigate DNA polymorphisms in susceptibility MASLD establish an AI model screening. METHODS...
ABSTRACT Background and Aim The relapse pattern following the discontinuation of tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to compare 2‐year incidences virological clinical relapses among who discontinued TAF versus those disoproxil fumarate (TDF) or entecavir (ETV). Methods multicenter retrospective enrolled noncirrhotic e antigen (HBeAg)‐negative CHB TAF, TDF, ETV undetectable HBV DNA at treatment cessation. For switched from...
Chronic hepatitis B virus (HBV) infection is associated with potential complications of liver cirrhosis and hepatocellular carcinoma. To date, there are no effective noninvasive clinical markers that can predict the risk fibrosis early accurately in chronic (CHB) patients treated nucleos(t)ide analogs (NAs). This study aimed to investigate association circulating let-7b/c/g levels severity hepatic a FIB-4 index 1.5-2.9 CHB patients. We conducted retrospective longitudinal after 6 months NAs...
Abstract Nucleotide analogs (NAs) reduced hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients. Among low‐viral‐load (DNA of virus [HBV] were <2000 IU/mL) and non‐cirrhotic CHB patients, the efficacy NAs prevention HCC remained elusive. The retrospective study recruited patients with e‐antigen (HBeAg) negative who older than 50 years. Patients treated or without (2:1 age sex match). survey was performed during regular follow‐up. A total 63 for current (mean age,...
Abstract Hepatitis D virus (HDV) infection increases the risk of hepatocellular carcinoma (HCC) in natural course chronic hepatitis B (CHB) patients. Its role patients treated with nucleotide/nucleoside analogues (NAs) is unclear. We aimed to study development HCC CHB NAs. Altogether, 1349 NAs were tested for anti-HDV antibody and RNA. The incidence factors analyzed. Rates HDV RNA positivity 2.3% 1.0%, respectively. annual was 1.4 per 100 person-years after a follow-up period over 5409.5...
Abstract We aimed to investigate the association between air pollution and advanced fibrosis among patients with metabolic associated fatty liver disease (MAFLD) chronic hepatitis B virus (HBV) C (HCV) infections. A total of 1376 participants who were seropositive for HBV surface antigen (HBsAg) or antibodies HCV (anti‐HCV) had abnormal function in a community screening program from 2019 2021 enrolled assessment using transient elastography. Daily estimates pollutants (particulate matter...
The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and risks B virus (HBV), C (HCV) D (HDV) IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) HDV (anti-HDV), load genotypes were measured 1137(67.0%) 1697 prisoners. 89.2% participants IDUs none had HIV infection. HBsAg, anti-HCV, dual HBsAg/anti-HCV, HBsAg/anti-HDV, triple HBsAg/anti-HCV/anti-HDV was 13.6%, 34.8%,...
Transfusion dependent subjects are at a great risk of viral hepatitis infection. We aimed to evaluate the prevalence and factors associated with B virus (HBV) C (HCV) infection among transfusion-dependent patients in Taiwan.A total 140 (67 thalassemic patients, 70 hemophilic two hereditary spherocytosis one patient von Willebrand disease) were prospectively enrolled spontaneous HCV clearance. All tested for HBV serology virology. Two consecutive serum samples, least 1 year apart, collected...
Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis metabolic dysfunction‐associated fatty disease (MAFLD) patients with or without viral hepatitis is elusive. AST to platelet ratio index (APRI), fibrosis‐4 (FIB‐4), and NAFLD score (NFS) were assessed 871 MAFLD who received elastography a hepatitis‐endemic area. area under the receiver operating characteristic (AUROC) curve increased substantially increasing fibrotic stage across three biomarkers. APRI (AUROC range...
Abstract Background and Aim The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development chronic hepatitis B (CHB)‐related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated ETV those TDF is unclear. Methods A total 2542 either or were recruited from a multinational cohort. 1:1 propensity score matching was performed to balance differences baseline characteristics two patient groups. We...
Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations CHC are associated with metabolic dysfunction-associated steatotic (MASLD). We aimed to elucidate whether virus (HCV) eradication mitigates MASLD occurrence or resolution. enrolled 5,840 patients whose HCV was eradicated by direct-acting antivirals nationwide registry. and the cardiometabolic risk factors (CMRFs) were evaluated at baseline 6 months after cure. There 2,147 (36.8%) SLD,...
To investigate the association between air pollution and hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues.
Prisoners are at risk of hepatitis C virus (HCV) infection, especially among the people who inject drugs (PWID). We implemented an outreach strategy in combination with universal mass screening and immediate onsite treatment a simplified pan-genotypic direct-acting antivirals (DAA) regimen, 12 wk sofosbuvir/velpatasvir, PWID-dominant prison Taiwan.To implement DAA regimen Taiwan.HCV-viremic patients were recruited for program HCV micro-elimination pangenotypic sofosbuvir/ velpatasvir, from...
Biochemical response is an important prognostic indicator in chronic hepatitis B (CHB) patients receiving nucleotide/nucleoside analogues (NAs). However, the effects of air pollution alanine aminotransferase (ALT) normalization remain elusive. This longitudinal study recruited 80 e antigen–negative CHB who received NAs. ALT levels were measured during first year anti-hepatitis virus therapy. Normal defined as <19 U/L for females and <30 males, risk factors associated with abnormalities...
Abstract Background & Aims Gamma‐glutamyl transferase (GGT) has been predictive of chronic hepatitis C‐related hepatocellular carcinoma (HCC) development. Its role in the risk HCC B (CHB) patients treated with nucleotide/nucleoside analogues (NAs) is elusive. Methods A total 2172 CHB from East Asia were randomized into development and validation groups a 1:2 ratio. Serum GGT levels before 6 months (M6) after initiating NAs potential factors measured. The primary endpoint was 12 NA...
Background/aims Hepatitis C virus (HCV) infection is associated with extrahepatic manifestations such as metabolic abnormalities. The association between chronic hepatitis (CHC) and uric acid levels has rarely been investigated. We aimed to evaluate the of serum in CHC patients. Methods Three hundred seventy-three histologically confirmed patients who were scheduled receive antiviral therapy consecutively enrolled, 746 age- sex-matched uninfected controls included for comparison....
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) DAAs might limit clinical practice this special population.Methods: The number, class, characteristics of DDIs five DAA regimens were analyzed among HCV-viremic from 23 hemodialysis centers Taiwan.Results: Of 2,015 screened 2019,...
Disease severity across the different diagnostic categories of metabolic dysfunction-associated fatty liver disease (MAFLD) remains elusive. This study assessed fibrosis stages and features MAFLD between items. We also aimed to investigate associations advanced risk factors.This multicenter cross-sectional enrolled adults participating in screening community. Patients were stratified following criteria, group A (395 patients) for type 2 diabetes, B (1,818 body mass index (BMI)>23 kg/m2, C...